| Biomarker ID | 1724 |
| PMID | 30777394 |
| Year | 2019 |
| Biomarker | CRIP3 |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Urine |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 1.079 (95% CI: 1.013-1.15) |
| Effect on Pathways | Pathway include: ROR1 human kinase ARCHS4 coexpression |
| Experiment | Reclassification (Progression Vs No Progression) |
| Type of Biomarker | Prognostic |
| Cohort | 109 patients with Prostate Cancer were selected for the study. Out of which 23 patients were reclassified: |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.017 |
| Method Used | qPCR-based MethyLight assay |
| Clinical | No |
| Remarks | Patients were considered reclassified if they experienced Gleason Grade increase on repeat biopsy |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |